Le Bonheur Children's Hospital cardiologists have implanted the world's first commercially-approved medical device for transcatheter patent ductus arteriosus closure in the tiniest babies (weighing as little as two pounds).
The Amplatzer Piccolo Occluder, developed by the global healthcare company Abbott, is a self-expanding, wire mesh device inserted through a small incision in the leg and guided through vessels to the heart, where it is placed to seal the opening of the heart.
Dr. Shyam Sathanandam, MD, medical director of Le Bonheur’s Interventional Cardiac Imaging and Interventional Catheterization Laboratory, helped pioneer the transcatheter closure before joining an 8-site FDA-approved trial for the Amplatzer Piccolo Occluder used in the closure. Le Bonheur enrolled more neonates than any other center in the study.
Shyam and his team closed the PDA in the first patient post-approval, a 2-week old baby girl, born at 28 weeks and weighing one kilogram.
Abbott’s Piccolo device is smaller than a pea and now offers hope to premature infants and newborns who need corrective treatment, and who may be non-responsive to medical management and high risk to undergo corrective surgery.
Approximately 60,000 premature babies in the U.S. are born each year with a very low birth weight, and nearly 12,000 (one out of five) of these have a significant PDA which will require urgent treatment for the baby to survive.
Le Bonheur Children’s Hospital in Memphis, Tenn., treats children each year through community programs, regional clinics and a 255 bed state-of-the-art hospital.
Le Bonheur serves as a primary teaching affiliate for the University Tennessee Health Science Center and trains more than 350 pediatricians and specialists each year. Nationally recognized, Le Bonheur is ranked by U.S. News & World Report as a Best Children’s Hospital.
Source: Company Press Release